A phase ii trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 2, 2013, Pages 151-156

  Hosein, Peter J ^a   De Lima Lopes Jr , Gilberto ^b   Pastorini, Vitor H ^a   Gomez, Christina ^a   MacIntyre, Jessica ^a   Zayas, Gloria ^a   Reis, Isildinha ^a   Montero, Alberto J ^a   Merchan, Jaime R ^a   Rocha Lima, Caio M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins Singapore   (Singapore)

Author keywords

chemotherapy; nab paclitaxel; pancreatic cancer; SPARC

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CLIVATUZUMAB TETRAXETAN Y 90; CONTRAST MEDIUM; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; IXABEPILONE; OSTEONECTIN; OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOCALCEMIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; CA-19-9 ANTIGEN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876159000     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182436e8c     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225-249.
2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
3. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinote-can [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol. 2010;28(15 suppl):4010.
4. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol. 2008;26(15 suppl):4508.
5. Heinemann V, Philip PA, Pelzer U. Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointest Cancer Res. 2009;3(5 suppl 2) 43-47.
6. Garber K. Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst. 2010;102:448-450.
7. Von Hoff DD, Korn R, Mousses S. Pancreatic cancer-could it be that simple? A different context of vulnerability. Cancer Cell. 2009;16:7-8.
8. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.
9. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-325.
10. Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 2008;19:899-909.
11. Maitra A, Rajeshkumar NV, Rudek M, et al. nab-Paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models. Mol Cancer Ther. 2009;8(12 suppl):C246.
12. Von Hoff DD, Ramanathan R, Borad M, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study. J Clin Oncol. 2009;27(15 suppl):4525.
13. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0, 2003. Available at: http://ctep.cancer.gov/reporting/ctc.html (accessed December 16, 2011).
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
15. Armitage P, Berry G. Matthews JNS. Statistical Methods in Medical Research. 4th ed. Oxford: Blackwell Scientific; 2002.
16. Oettle H, Arnold D, Esser M, et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs. 2000;11:635-638.
17. Cereda S, Reni M. Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemo-ther. 2008;20:509-512.
18. Lopes G, Rocha Lima CM. Docetaxel in the management of advanced pancreatic cancer. Semin Oncol. 2005;32(2 suppl 4): S10-S23.
19. Desai N, Trieu VN, Hwang L, et al. Use of CA19-9 and SPARC to predict outcome in a phase I/II study of nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer. Presented at the 2010 Molecular Markers meeting, Hollywood: FL; Abstract available at: http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview = abst-detail-view&confID = 101&abstractID = 61020 (accessed December 16, 2011).